Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

620 ARTÍCULOS , VIENDO DEL 361 AL 375

Blood-Brain Barrier Opening with MRI-guided Focused Ultrasound Elicits Meningeal Venous Permeability in Humans with Early Alzheimer Disease

Mehta RI, Carpenter JS, Mehta RI, Haut MW, Ranjan M, Najib U, Lockman P, Wang P, D'haese PF, Rezai AR.

Radiology. 2021 Mar;298(3):654-662. doi: 10.1148/radiol.2021200643. Epub 2021 Jan 5.

Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis

Liss JL, Seleri Assunção S, Cummings J, Atri A, Geldmacher DS, Candela SF, Devanand DP, Fillit HM, Susman J, Mintzer J, Bittner T, Brunton SA, Kerwin DR, Jackson WC, Small GW, Grossberg GT, Clevenger CK, Cotter V, Stefanacci R, Wise-Brown A, Sabbagh MN.

J Intern Med. 2021 Aug;290(2):310-334. doi: 10.1111/joim.13244. Epub 2021 Mar 31.

Radioactive synthesis of tau PET imaging agent (18)F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis

Zhang W, Xu S, Yu H, Li X, Jin Z, Li Y, He Z.

Ann Nucl Med. 2021 Feb;35(2):139-147. doi: 10.1007/s12149-020-01566-4. Epub 2021 Jan 18.

Functional nanoassemblies for the diagnosis and therapy of Alzheimer's diseases

Zhang L, Sun H, Chen Y, Wei M, Lee J, Li F, Ling D.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Jul;13(4):e1696. doi: 10.1002/wnan.1696. Epub 2021 Jan 18.

Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development

Wessels AM, Edgar CJ, Nathan PJ, Siemers ER, Maruff P, Harrison J.

Drug Discov Today. 2021 May;26(5):1330-1336. doi: 10.1016/j.drudis.2021.01.012. Epub 2021 Jan 21.

Chalcone and its analogs: Therapeutic and diagnostic applications in Alzheimer's disease

Thapa P, Upadhyay SP, Suo WZ, Singh V, Gurung P, Lee ES, Sharma R, Sharma M.

Bioorg Chem. 2021 Mar;108:104681. doi: 10.1016/j.bioorg.2021.104681. Epub 2021 Jan 29.

The application of multifunctional nanomaterials in Alzheimer's disease: A potential theranostics strategy

Xu Y, Zhao M, Zhou D, Zheng T, Zhang H.

Biomed Pharmacother. 2021 May;137:111360. doi: 10.1016/j.biopha.2021.111360. Epub 2021 Feb 11.

A review on α-mangostin as a potential multi-target-directed ligand for Alzheimer's disease

Yang A, Liu C, Wu J, Kou X, Shen R.

Eur J Pharmacol. 2021 Apr 15;897:173950. doi: 10.1016/j.ejphar.2021.173950. Epub 2021 Feb 16.

KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers

Belloy ME, Eger SJ, Le Guen Y, Napolioni V, Deters KD, Yang HS, Scelsi MA, Porter T, James SN, Wong A, Schott JM, Sperling RA, Laws SM, Mormino EC, He Z, Han SS, Altmann A, Greicius MD; A4 Study Team; Insight 46 Study Team; Australian Imaging Biomarkers and Lifestyle (AIBL) Study; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2021 May;101:123-129. doi: 10.1016/j.neurobiolaging.2021.01.008. Epub 2021 Jan 23.

Role of natural products for the treatment of Alzheimer's disease

Noori T, Dehpour AR, Sureda A, Sobarzo-Sanchez E, Shirooie S.

Eur J Pharmacol. 2021 May 5;898:173974. doi: 10.1016/j.ejphar.2021.173974. Epub 2021 Feb 27.

Crosstalk between Gut and Brain in Alzheimer's Disease: The Role of Gut Microbiota Modulation Strategies

Shabbir U, Arshad MS, Sameen A, Oh DH.

Nutrients. 2021 Feb 21;13(2):690. doi: 10.3390/nu13020690.

Donanemab in Early Alzheimer's Disease

Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM.

N Engl J Med. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13.

Virtual care for patients with Alzheimer disease and related dementias during the COVID-19 era and beyond

Gosse PJ, Kassardjian CD, Masellis M, Mitchell SB.

CMAJ. 2021 Mar 15;193(11):E371-E377. doi: 10.1503/cmaj.201938.

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL.

Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias